UK-based Autolomous, a cloud-based, cell and gene therapy (CGT) software platform developer, announced on Jan. 20, 2025 that it has partnered with US-based Trenchant BioSystems, a CGT manufacturing platform developer for gene-modified cells, to combine technology platforms to address timelines, costs, and challenges with CGT manufacturing. Under the partnership, Trenchant will integrate Autolomous’ autoloMATE digital solution into their automated CGT manufacturing platform. Source: Biopharm International 23/1/2025